Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	828.90B +178.0%
Revenue (ttm)	211.13B +42.7%
Net Income	17.80B
EPS	1,290.73
Shares Out	12.95M
PE Ratio	49.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,783
Average Volume	78,284
Open	66,300
Previous Close	68,200
Day's Range	62,900 - 67,000
52-Week Range	22,000 - 72,700
Beta	0.06
RSI	61.98
Earnings Date	Mar 18, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2000
• Employees: 426
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.